Tonix Pharmaceuticals CEO on New Fibromyalgia Drug TNX-102-SL

TNX-102-SL: A New Approach to Fibromyalgia

• 💡 Tonix Pharmaceuticals is nearing FDA approval for TNX-102-SL, a new medication for fibromyalgia, marking the first new drug for the condition in 15 years.
• 🎯 The drug targets nonrestorative sleep, a key symptom in fibromyalgia sufferers, aiming to improve overall well-being.
• 💊 TNX-102-SL is a sublingual tablet taken nightly, designed as a non-opioid analgesic for chronic pain.

FDA Approval and Launch Timeline

• 📅 Tonix has a Prescription Drug User Fee Act (PDUFA) date of August 15 for an FDA decision on marketing authorization in the United States.
• 🚀 If approved, the company anticipates a commercial launch approximately two months after approval.
• 📈 This marks a significant milestone, as developing a new drug can take many years, and Tonix has been working on this program for a decade.

Business and Financial Outlook

• 💰 Tonix Pharmaceuticals reported approximately $100 million in cash at the end of Q4 2024 and raised an additional $45 million in Q1.
• ⏳ The company has sufficient cash to operate into the first quarter of 2026, supporting the upcoming drug launch.
• 🏢 With existing marketing of two prescription drug products for migraine, Tonix is preparing its commercial organization for the significant launch of TNX-102-SL.

Differentiating TNX-102-SL from Existing Treatments

• ⚠️ Current FDA-approved fibromyalgia treatments include Lyrica (pregabalin), Cymbalta (duloxetine), and Savaysa (milnacipran), with Lyrica and Cymbalta now generic.
• 🔬 TNX-102-SL represents a new class of medicines called tertiary amine tricyclic compounds.
• ✅ Unlike existing treatments, TNX-102-SL uniquely targets unrefreshing sleep and has demonstrated statistically significant reductions in pain with a favorable tolerability profile in studies.